Literature DB >> 32075190

Differential Secretion of Angiopoietic Factors and Expression of MicroRNA in Umbilical Cord Blood from Healthy Appropriate-For-Gestational-Age Preterm and Term Newborns-in Search of Biomarkers of Angiogenesis-Related Processes in Preterm Birth.

Dorota Gródecka-Szwajkiewicz1, Zofia Ulańczyk1, Edyta Zagrodnik1, Karolina Łuczkowska1, Dorota Rogińska1, Miłosz P Kawa1, Iwona Stecewicz1, Krzysztof Safranow2, Bogusław Machaliński1.   

Abstract

Objectives: Premature birth, defined as less than 37 weeks gestation, affects approximately 12% of all live births around the world. Advances in neonatal care have resulted in the increased survival of infants born prematurely. Although prematurity is a known risk factor for different cardiovascular diseases, little is known about the pathophysiology of vasculature during premature gestation and angiopoietic factors network during premature birth. Aims: The objective of this study was to determine whether the profile of several pro-angiogenic and anti-angiogenic factors in umbilical cord blood (UCB) is different in healthy appropriate-for-gestational-age preterm newborns and normal term babies. The second aim of this study was to investigate the microRNA (miRNAs) expression profile in UCB from preterm labor and to detect miRNAs potentially taking part in control of angogenesis-related processes (Angio-MiRs).
Methods: Using an immunobead Luminex assay, we simultaneously measured the concentration of Angiogenin, Angiopoietin-1, FGF-acidic, FGF-basic, PDGF-aa, PlGF, VEGF, VEGF-D, Endostatin, Thrombospondin-2, NGF, BDNF, GDNF, and NT-4 in UCB samples collected from the preterm (n = 27) and term (n = 52) delivery. In addition, the global microRNA expression in peripheral blood mononuclear cells (PBMCs) circulating in such UCB samples was examined in this study using microarray MiRNA technique.
Results: The concentrations of five from eight measured pro-angiogenic factors (VEGF, Angiopoietin-1, PDGF-AA, FGF-a, and FGF-b) were significantly lower in UCB from preterm newborns. On the contrary, two angiostatic factors (Endostatin and Thrombospondin-2) were significantly up-regulated in preterm UCB. Among analyzed neurotrophins in preterm newborns, the elevated UCB concentration was found only in the case of GDNF, whereas BDNF was significantly reduced. Moreover, two angiopoietic factors, VEGF-D and PlGF, and two neurotrophins, NT4 and NGF, did not differ in concentration in preterm and term babies. We also discovered that among the significantly down-regulated miRNAs, there were several classical Angio-MiRs (inter alia MiR-125, MiR-126, MiR-145, MiR-150, or MiR155), which are involved in angiogenesis regulation in newborn after preterm delivery. Conclusions: This is the first report of simultaneous measurements of several angiopoietic factors in UCB collected from infants during preterm and term labor. Here, we observed that several pro-angiogenic factors were at lower concentration in UCB collected from preterm newborns than term babies. In contrast, the two measured angiostatic factors, Endostatin and Thrombospondin-2, were significantly higher in UCB from preterm babies. This can suggest that distinct pathophysiological contributions from differentially expressed various angiopoietic factors may determine the clinical outcomes after preterm birth. Especially, our angiogenesis-related molecules analysis indicates that preterm birth of healthy, appropriate-for-gestational-age newborns is an "anti-angiogenic state" that may provide an increased risk for improper development and function of cardiovascular system in the adulthood. This work also contributes to a better understanding of the role of miRNAs potentially involved in angiogenesis control in preterm newborns.

Entities:  

Keywords:  angiogenesis; angiopoietic factors; angiostatic factors; appropriate-for-gestational-age preterm newborns; microRNA; peripheral blood; prematurity; preterm gestation; pro-angiogenic factors; umbilical cord blood

Year:  2020        PMID: 32075190     DOI: 10.3390/ijms21041305

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  5 in total

1.  Extracellular vesicle microRNA in early versus late pregnancy with birth outcomes in the MADRES study.

Authors:  Caitlin G Howe; Helen B Foley; Elizabeth M Kennedy; Sandrah P Eckel; Thomas A Chavez; Dema Faham; Brendan H Grubbs; Laila Al-Marayati; Deborah Lerner; Shakira Suglia; Theresa M Bastain; Carmen J Marsit; Carrie V Breton
Journal:  Epigenetics       Date:  2021-03-18       Impact factor: 4.528

Review 2.  The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity.

Authors:  Josine E G Vaes; Myrna J V Brandt; Nikki Wanders; Manon J N L Benders; Caroline G M de Theije; Pierre Gressens; Cora H Nijboer
Journal:  Glia       Date:  2020-11-30       Impact factor: 7.452

3.  Comparative Analysis of Global Gene Expression and Complement Components Levels in Umbilical Cord Blood from Preterm and Term Neonates: Implications for Significant Downregulation of Immune Response Pathways related to Prematurity.

Authors:  Dorota Gródecka-Szwajkiewicz; Zofia Ulańczyk; Edyta Zagrodnik; Karolina Łuczkowska; Dorota Rogińska; Miłosz P Kawa; Iwona Stecewicz; Krzysztof Safranow; Przemysław Ustianowski; Sławomir Szymański; Bogusław Machaliński
Journal:  Int J Med Sci       Date:  2020-07-11       Impact factor: 3.738

4.  Neurotrophic Factor Levels in Preterm Infants: A Systematic Review and Meta-Analysis.

Authors:  Francieli Cristina Krey; Bruna Alvim Stocchero; Kerstin Camile Creutzberg; Bernardo Aguzzoli Heberle; Saulo Gantes Tractenberg; Li Xiang; Wei Wei; Bruno Kluwe-Schiavon; Thiago Wendt Viola
Journal:  Front Neurol       Date:  2021-04-01       Impact factor: 4.003

Review 5.  MiR-125 Family in Cardiovascular and Cerebrovascular Diseases.

Authors:  Yang Wang; Jing Tan; Lu Wang; Gaiqin Pei; Hongxin Cheng; Qing Zhang; Shiqi Wang; Chengqi He; Chenying Fu; Quan Wei
Journal:  Front Cell Dev Biol       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.